Krajina: Austrália
Jazyk: angličtina
Zdroj: Department of Health (Therapeutic Goods Administration)
ramipril, Quantity: 10 mg
Arrotex Pharmaceuticals Pty Ltd
Ramipril
Tablet, uncoated
Excipient Ingredients: sodium stearylfumarate; pregelatinised maize starch; croscarmellose sodium; sodium bicarbonate; lactose monohydrate
Oral
30
(S4) Prescription Only Medicine
? Treatment of hypertension. Data are currently not available to support the use of Ramipril in renovascular hypertension. ,? Post MI heart failure ,? Prevention of progressive renal failure in patients with persistent proteinuria in excess of 1 g/day. ,? For reducing the risk of myocardial infarction, stroke, cardiovascular death or the need for revascularisation procedures in patients 55 years of age or more who have clinical evidence of coronary artery disease, stroke, or peripheral vascular disease. ,? For reducing the risk of myocardial infarction, stroke, cardiovascular death or revascularization procedures in diabetic patients 55 years or more with one or more of the following risk factors: systolic blood pressure >160mmHg or diastolic blood pressure >90mmHg (or on antihypertensive treatment); total cholesterol >5.2mmol/L; HDL cholesterol <0.9mmol/L; current smoker; known microalbuminuria; any evidence of previous vascular disease.
Visual Identification: White to off-white coloured, flat faced bevel edged round uncoated tablet debossed with 'H' & '20' separated by score line on one side and plain on other side; Container Type: Bottle; Container Material: HDPE; Container Life Time: 2 Years; Container Temperature: Store below 25 degrees Celsius; Container Closure: Child resistant closure
Licence status A
2011-10-06